This website uses technical, customisation and analytical cookies, both first-party and third-party, to anonymously facilitate browsing and analyse statistics on use of the website. Learn more
Search results
-
Gilead: Hepatitis-C Access Strategy (A)
Rangan, V. Kasturi; Rangan, Vikram; Bloom, David E.Case HBS-515025-EGilead had come up with an innovative drug for Hepatitis C, which affected 180 million people worldwide. The drug was priced at $1,000 a pill for the US market. Gilead had to decide how to price and market the pill in developing countries that bore the brunt of the disease. The company had earned accolades for its work in HIV/AIDS, where its innovative medicines now accounted for 60% of all patients on Anti-Retroviral (ARV) medicines. Much of thi...Starting at €8.20
-
Gilead: Hepatitis C Access Strategy (B)
Rangan, V. KasturiCase HBS-515044-EWhile the Gilead: Hepatitis-C Access Strategy (A) case (515-025) poses questions on what the company should do with respect to hart hit countries like Egypt and India, this (B) case provides the answer. In both cases, the company chose to pursue a proactive strategy to enable access at affordable prices.Starting at €5.74
-
Erik Peterson at Biometra (C)
Gabarro, John J.; DeLong, Thomas J.; Soo, JevanCase HBS-411033-ELeadership and People ManagementDescribes the outcome of Erik Peterson's meetings over the course of two days with a number of senior executives from the parent company. Students should have read the (A) and (B) cases. The (C) case may be assigned with the (D) case. A redisguised and updated version of earlier case 494-007.Starting at €5.74
-
Erik Peterson (C) (Spanish version)
Gabarro, John J.Case HBS-404S05Leadership and People ManagementDescribes the outcome of Erik Peterson's one-day meeting with his superior and the events of the subsequent day's meeting with the president and vice president of operations of the parent company. Students should have read the (A) and (B) cases. The (C) case may be assigned with the (D) case. A redisguised version of an earlier case.Starting at €5.74
-
Equitas Microfinance (C): Advent of Regulation
Narayanan, V.G.; Rangan, V. Kasturi; Muthuram, VidhyaCase HBS-113006-ESupplement for case 510104Starting at €5.74
-
Atlas-Copco (C): El episodio del conflicto
Rangan, V. KasturiCase HBS-509S23MarketingDescribe la respuesta de la empresa a otros problemas con un distribuidor.Starting at €5.74
-
Gilead: Hepatitis-C Access Strategy (A) and (B), Teaching Plan
Rangan, V. KasturiTeaching Note HBS-520063-ETeaching plan for cases 515025 and 515044.Starting at €0.00
-
General Electric Plastics: Organización de la Función Comercial
Rangan, V. Kasturi; Michael, Steven C.Case HBS-505S18MarketingDescribe el rápido crecimiento de General Electric Plastics de durante la última década a un (ventas) compañía de $ 5 mil millones. Se describen las transiciones de organización de acompañamiento. La tarea es diseñar una organización de marketing para la próxima década debido a los cambios de mercado previstos.Starting at €8.20
-
Sustainability at Siemens
Rangan, V. Kasturi; Edmondson, Amy C.; Beyersdorfer, Daniela; Moloney, EmerCase HBS-514026-EKnowledge and CommunicationDescribes sustainability efforts at Siemens since arrival of Chief Sustainability Officer, Barbara Kux, in 2008. Asks students to evaluate success of those efforts and outline what the company should do going forward.Starting at €8.20
-
Erik Peterson (E) (Spanish version)
Gabarro, John J.Case HBS-408S13Leadership and People ManagementPresents the final outcome of the events. The William Jurgens case presents a description from the corporation president's point of view of the series of events (as reported in the Erik Peterson (A), (B), (C), and (D) cases). The Jurgens case can be assigned with Erik Peterson (E) to give a broader perspective on Olafson's behavior and problems. This case can be handed out during class discussion of the (D) case. A redisguised version of an earli...Starting at €5.74